SANTERO was founded by Abel Garcia-Pino, Cédric Govaerts in 2021.

Who are SANTERO's investors?

SANTERO's investors include Newton Biocapital, Sambrinvest.

Where is SANTERO headquartered?

SANTERO is headquartered in Brussels, BE.

SANTERO

Brussels, BE · Founded 2021 · 24 employees on LinkedIn · 4 known investors

Find your way into SANTERO

Paths you didn't know you had: your email and LinkedIn already hold routes to the SANTERO team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Santero is a Belgium-based biotech company developing antibacterial drugs, including an RSH inhibitor programme targeting Pseudomonas aeruginosa and multidrug-resistant pathogens. It runs drug discovery and preclinical development spanning computational chemistry, medicinal chemistry, and screening toward clinical development.

AI & Machine Learning Biotech Deep Tech Healthtech

Founders & leadership

SANTERO was founded in 2021 by Abel Garcia-Pino and Cédric Govaerts.

Abel Garcia-PinoCo-founder & Scientific Advisor

Cédric Govaerts Co-founder & Scientific AdvisorBoard Member at Fund+

Mark Beards Chief Executive OfficerMark Beards is CEO of Santero, a Belgium-based biotech company developing antibacterial drugs targeting multidrug-resistant pathogens. He has held leadership roles in medtech and biotech start-ups, large pharma, and investment banking, with experience in capital raising, product launches, and M&A.

Emilie RacineCOO & Head of Chemistry

Cuong Vuong Chief Scientific OfficerHe brings over 16 years of pharmaceutical and biotech industry experience and more than 20 years in life sciences and infectious diseases research, with expertise spanning drug discovery, preclinical development, and project validation across small molecules, natural products, peptides, phages, and engineered lysins.

Valérie GallienChief of Staff

Investors · 4

Newton Biocapitallisted by Newton BiocapitalBrussels

How we know: Newton Biocapital's portfolio page · funding news · biospace.com · the VCSheet dataset · Not right? Tell us

SambrinvestreportedCharleroi

How we know: biospace.com · Not right? Tell us

Also in the syndicate · 2

SFPIMWE Life Sciences

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AJun 2023
Newton Biocapital (lead), Sambrinvest, SFPIM, WE Life Sciences
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

SANTERO announces a €8 million Series A funding round led by Newton Biocapital to develop novel antibiotics in the fight against antimicrobial resistance. - BioSpacebiospace.com · Jun 2023

Frequently asked questions

What does SANTERO do?: Santero is a Belgium-based biotech company developing antibacterial drugs, including an RSH inhibitor programme targeting Pseudomonas aeruginosa and multidrug-resistant pathogens. It runs drug discovery and preclinical development spanning computational chemistry, medicinal chemistry, and screening toward clinical development.
Who founded SANTERO?: SANTERO was founded by Abel Garcia-Pino, Cédric Govaerts in 2021.
Who are SANTERO's investors?: SANTERO's investors include Newton Biocapital, Sambrinvest.
Where is SANTERO headquartered?: SANTERO is headquartered in Brussels, BE.